Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
August 28, 2019 8:30 AM EDT- Five abstracts accepted, including new long-term data from PREVENT trial of SOLIRIS® (eculizumab) in adults with anti-AQP4 antibody-positive NMOSD -
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that five abstracts from the Phase 3 PREVENT study of SOLIRIS® (eculizumab) in neuromyelitis optica spectrum disorder (NMOSD)... More
Alexion to Present at the 14th Annual Citi Biotech Conference
August 28, 2019 6:30 AM EDTBOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.m., ET.
An audio webcast of the presentation will be... More
